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International research guidelines1-4 and researchers5,6 em-
phasise the universal recognition of informed consent as a pre-
condition for ethical and scientific research involving human 
participants. Informed consent ensures respect for individual 
autonomy6 and safeguards against abuses of the participants. 
However, informed consent continues to be ignored3 and its 
practice remains an isssue of concern.7,8 Institutional review 
boards that regulate clinical research focus on the protocol and 
content of the consent form, rather than on ensuring that the ac-
tual process of obtaining consent is appropriate.9 However, the 
World Health Organization10 recommends that institutional re-
view boards monitor studies once they have begun. The author 
argues that monitoring of studies should include the enrolment 
of participants, which involves the process of informed consent 
administration.
In many studies, participants are exploited and the elements 
of informed consent are not fully observed. A high prevalence of 
poverty, inaccessible healthcare services and low literacy levels in 
developing countries are among the reasons for increased vulner-
ability of participants to research exploitation.11 With the existing 
threats of HIV/AIDS, malaria and tuberculosis as the top killer dis-
eases globally, biomedical research involving human participants 
is rapidly expanding.
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Background. Informed consent ensures respect for individual autonomy and safeguards against abuses of human participants. How-
ever, the high prevalence of poverty, inaccessibility of healthcare services, diseases, social insecurity and low literacy in developing 
countries such as Kenya increases participants’ vulnerability to research exploitation and abuse. Biomedical and behavioural studies 
conducted on the vulnerable population in Kenya raise concerns about voluntary participation.
Objective. The purpose of this study was to assess the process of obtaining informed consent by postgraduate students in the Col-
lege of Health Sciences at the University of Nairobi, Kenya.
Method. The study was observational, descriptive and quantitative. A convenience sample of 20 postgraduate students at the data 
collection stage was selected to participate in the study. Each student was observed during four episodes of administering informed 
consent, totalling 80 episodes of observed student-subject interaction. Data were collected for a period of 6 weeks by means of an ob-
servation checklist and analysed using the SPSS version 14 computer package. Descriptive statistics were used to answer the research 
questions.
Results. The main finding was that performance scores were better on the items that had a positive influence on patient participation 
than on those that would negatively influence patient participation.
Conclusions. The consent form was mainly used for the students’ legal protection and not for the patients’ benefit.
Recommendation. A further study on a large sample drawn from all the schools of the college is needed to confirm the practice of 
obtaining informed consent  and compare performance in all the schools.
S Afr J BL 2012;5(1):45-50.
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Kenya is a resource-poor country with over 40% of the popula-
tion unemployed and approximately 50% of people living below 
the poverty line.12 Biomedical studies are increasingly being con-
ducted on vulnerable Kenyan communities, and concerns about 
voluntary participation are on the increase. Evidence on whether 
researchers in Kenya obtain informed consent is lacking. An audit 
on the administration of informed consent would provide data on 
whether research participation in Kenya is voluntary. Since post-
graduate students (PGSs) form 73% of biomedical researchers in 
Kenya,13 an audit of their practice of obtaining informed consent 
would provide data on the quality of informed consent obtained.
Method
A descriptive, quantitative study using a structured observation 
checklist was conducted among PGSs of the College of Health 
Sciences (CHS). A convenience sample of 20 PGSs was selected 
by the ‘snowballing’ technique, for logistical reasons and because 
of reluctance to participate. Data were collected for a period of 
6 weeks. Four episodes of consent administration for each PGS 
were observed to take care of the Hawthorne effect. This is be-
cause observing the PGS administer the informed consent to four 
prospective participants would allow the researcher to observe 
and validate inconsistencies in behaviour that could occur as a 
result of being observed.
A sampling frame of all part 2 PGSs at the CHS was obtained 
from the respective schools’ administrations. PGSs studying at 
Kenyatta National Hospital (KNH) were identified and visited in the 
clinical areas. The first PGS met was approached and given full 
disclosure of the research information and time to make a decision 
on participation. An appointment was subsequently arranged with 
the PGS, whose comprehension of information about the study 
was assessed using the questionnaire for objective responses be-
fore obtaining informed consent.
Data were collected using an observation checklist containing 9 
elements of informed consent adapted from the US Code of Fed-
eral Regulations (45CFR 6.116[c&d]). Modification of the checklist 
was done to include demographic characteristics of the PGSs and 
methods used to elicit the elements. Each PGS was observed ad-
ministering informed consent to 4 patients (4 episodes), totalling 
80 episodes of observed interaction between PGSs and patients. 
Data input and analysis were done using the SPSS version 14 
computer package. Descriptive statistics and clustered analyses 
were used to answer research questions.
Ethical issues
The study was approved by the KNH/CHS Ethics and Research 
Committee (ERC) and the Vice-Chancellor of the University. In-
formed consent was obtained, and neither incentives nor compen-
sation were given to PGSs since they were observed in the course 
of their normal research activity. No more than minimal risks were 
associated with the study. The PGSs were informed that the prin-
cipal investigator was conducting this research as part of a course 
requirement and was therefore observing them in her capacity as 
a student of research ethics with no conflicting interests.
Study limitations
The study employed a non-probability method in selecting a sam-
ple of 20 PGSs, mainly from the School of Medicine. Although 
there were limitations in methodology, such as the ‘snowballing’ 
sampling technique, the study did generate significant findings 
that need to be brought to the attention of bioethicists, research 
ethicists and institutional review boards. It can be treated as a pi-
lot study, and the findings remain significant since the PGSs who 
agreed to participate may have been those who were confident 
about their performance, implying that they could be performing 
better than their colleagues who declined participation.  
Results
This study targeted all PGSs from the CHS, but only PGSs from 
the schools of Medicine and Pharmacy participated. PGSs from 
the schools of Nursing and Dental Sciences were not at the data 
collection stage at the time of this study. The School of Medicine 
had the majority of participants (85%), with only 15% of PGSs from 
Pharmacy. Study findings indicated that 90% of the PGSs had 
taken a course in research methods as part of the undergraduate 
course units and as a 2-week common course taught to all PGSs 
in the CHS.
To audit the practice of administration of informed consent, the 
extent to which each PGS elicited all 9 elements was assessed. 
Elements were categorised into the 3 fundamental conditions 
mandatory for informed consent, i.e. full and complete provision 
of information, comprehension of information, and voluntary par-
ticipation. Each element contained sub-elements referred to as 
items, and it was considered elicited if a PGS addressed it irre-
spective of the number of episodes.
The performance score on the items was graded according to 
the number of times an item was elicited during the 4 episodes of 
consent administration. Since each student was observed on 4 
episodes, a score of 4 points (100%) was given for an item elic-
ited in all episodes. A zero (0%) score on an item indicated that it 
was not elicited at all. A grade was assigned to the score obtained 
on each element as follows: <50% = below average, 50 - 64% = 
average, 65 - 74% = above average, 75 - 84% = very good, and 
85 - 100% = excellent. 
Category A. Full and complete provision of 
information
This category contained 4 elements, namely:
• Element 1: Introduction to research activity
• Element 2: Description of risks and benefits
• Element 4: Assurance of anonymity and confidentiality
• Element 5: Compensation for participation in research.
Element 1: Introduction to research activity. This element 
had 11 items. Performance on these items is described below and 
summarised in Fig. 1.
The best performance was recorded on item 1.11, which as-
sessed the use of appropriate language. The majority (80%) of the 
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PGSs used official, national and the patients’ traditional language 
of communication in all the 4 episodes – an excellent score of 
95%.
 A very good score of 80% was observed on item 1.1, which 
assessed whether the PGSs explained to the patients that they 
were participating in a research activity. This item was elicited by 
all PGSs in varying numbers of episodes. Almost half (45%) of the 
PGSs elicited the item in all 4 episodes. Seventeen PGSs (85%) 
elicited the item in more than 50% of the episodes. The researcher 
was, however, surprised at the below-average (30%) performance 
on a related item 1.7, which required the PGSs to explain to the 
patients that they were being asked to be study participants. Al-
though item 1.7 was elicited in varying episodes by half (50%) of 
the students, only 3 (15%) of them elicited it in the 4 episodes and 
half (50%) of them completely failed to elicit it.
Item 1.2 recorded an above-average score of 65%, which was 
the third-best performance. The item required PGSs to explain the 
purpose of research to their patients. Eleven (55%) PGSs elicited 
this item in more than half of the episodes and 25% of the PGSs 
explained it in all the episodes.
The remaining 8 items recorded below-average scores (<50%).
The lowest scores were recorded on items 1.3 and 1.8. Item 1.3 re-
quired the PGSs to explain to the patients the approximate number 
of patients involved in the study, while item 1.8 required the PGSs to 
describe alternative procedures and courses of treatment available 
and their advantages. No PGSs elicited these items at all.
Element 2. Description of risks and discomforts. This ele-
ment had 6 items. The general performance on these items was 
below average (Fig. 2).
Item 2.1 involved describing foreseeable physical risks and 
discomforts to the patient. It recorded a score of below average 
(42.5%), yet it was the item with the highest performance on the el-
ement. More than half of the PGSs described risks and discomfort 
to patients in varying numbers of episodes. It is worth noting that 
only 3 (15%) of the PGSs described the risks to their patients in all 
4 episodes, while 7 (35%) did not elicit this item at all.
Items 2.2, 2.3, 2.4 and 2.5, which required the PGSs to describe 
foreseeable social, emotional, economic risks or discomforts and 
how they would be minimised, recorded a dismal performance 
(Fig. 2).
Element 4. Assurance of anonymity and confidentiality. This 
element had 2 items. They required explanation to patients about 
maintaining confidentiality during the research process and in pub-
lication. Forty per cent of the PGSs explained about confidentiality 
of records during the research process in varying number of epi-
sodes. However, no PGSs explained about confidentiality during 
publication of data in any episode.
Element 5. Compensation for participation in research. This 
element contained 3 items that required the PGSs to explain and 
describe availability of compensation, medical treatment and the 
risks if injury occurred. The performance in all these 3 items was 
below average, with the highest score 13.75%.
Category B. Comprehension of information
This category comprised two elements:
• Element 6: Offering answers to questions 
• Element 9: Assessment of participant understanding of informa-
tion.
Element 6 contained 4 items. The performance on this element 
was below average, with a range between 46.25% and 3.73%. 
Item 6.2, which assessed whether the PGSs allowed time for pa-
tients to ask questions, recorded the highest score. The majority 
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Fig. 1. Performance on element 1: introduction to research activity.
Fig. 2. Performance on element 2: description of risks and dis-
comfort.
    Article
(80%) of the PGSs allowed time for questions in varying number 
of episodes. Thirty per cent of them allowed for time in only 1 epi-
sode while 20% allowed for time in all 4 episodes. It is worth noting 
that no PGS assessed patients’ understanding of information, as 
required in element 9.
Category C. Voluntary participation 
This last category had three elements:
• Element 3: Description of benefits
• Element 7: Non-coercive disclaimer
• Element 8: Option to withdraw.
Element 3. Description of benefits. The element had 4 items 
concerned with description of direct, indirect, future and clinical bene-
fits. It was encouraging that all PGSs described the research benefits 
to their patients, although in varying numbers of episodes. The major-
ity (75%) of the PGSs described direct benefits in at least 3 episodes. 
The performance on this item was very good (77.5%). Items 3.1 and 
3.4, on future benefits of research to others and making patients 
aware of no clinical benefits, respectively, recorded below-average 
scores. However, item 3.2, on description of indirect benefits, was not 
elicited at all. Fig. 3 shows a summary of these scores.
Element 7. Non-coercive disclaimer. Element 7 had 2 items. 
The first item required the PGSs to explain to the patients that 
participation was voluntary. More than half (70%) of the PGSs 
elicited this item in varying number of episodes. Three PGSs 
(15%) elicited this item in all 4 episodes while 6 PGSs (30%) 
elicited the item in 3 episodes and 6 (30%) did not elicit the item 
at all. The second item, explaining that there would be no penal-
ties or loss of benefits for refusal to participate, was not elicited 
by any PGSs.
Element 8. Option to withdraw.The element had 2 items which 
were not elicited at all by any PGS. These items required the PGS 
to explain to patients the option to discontinue research at any 
time they wanted. The PGS was also required to explain that the 
patient would be stopped from participation at any time if his/her 
health was at risk.
Discussion
Introduction to research activity
Performance on the items ‘explanation of research activity’ (80%), 
‘use of appropriate language’ (95%) and ‘encouraging patients to 
ask questions’ (60%), could imply that the majority of the patients 
were aware of their participation in research activity. However, it 
is not clear whether the patients understood the nature of the re-
search they were participating in, since their understanding was 
not evaluated. Research has shown that patients may be aware 
they are taking part in a study without understanding its nature.14 
In some studies,10,15,16 participants mentioned the need to check 
their understanding of information at every step of the research 
process. Explaining the approximate number of participants in-
volved in the study and describing alternative procedures to par-
ticipants were the only items in the element not elicited at all. While 
it may be argued that describing the alternative procedures could 
have been missed out completely because of the nature of the 
research, namely prevalence studies that did not require such de-
scription, explaining the number of participants, which is relevant 
to all research studies, was also missed out completely for rea-
sons that are not clear.
Description of risks and discomforts
The PGSs seemed to have described mainly physical risks to 
patients, and recorded below-average (42.5%) performance. 
They may have found physical risks and discomfort easier to 
explain, since the majority of them conducted cross-section-
al studies in which most of the participants had their physi-
ological parameters observed without having to go through 
interventional procedures. Besides, invasive procedures per-
formed (such as drawing samples) carried minimal risks, be-
ing part of routine care that the patient would receive in the 
absence of research. 
Items on description of social risks, emotional risks, economic 
risks and how risks would be minimised recorded the lowest score 
(≤3%). Although the failure of PGSs to explain economic risks 
could be due to pressure of time, patients were recruited done in 
the course of clinical duties with many patients in the queue, lack 
of knowledge by the PGSs could not be ruled out. The PGSs were 
expected to anticipate patients’ anxiety associated with disclosing 
personal information and uncertainty on cost implications during 
participation, and address them accordingly. Low scores on the 
element could be attributed to association of risks with clinical tri-
als and not with cross-sectional surveys that formed the majority 
(80%) of the PGSs’ studies.
 rticle
Fig. 3. Performance on element 3: description of benefits.
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Assurance of anonymity and confidentiality
Participants value anonymity and confidentiality, and this influ-
ences their participation in research. It appears that PGSs were 
concerned with research as part of the course requirement and 
not with regard to publishing findings, which could explain their 
failure to mention confidentiality on published data. The find-
ings were consistent with a study in which only 30% of the par-
ticipants remembered being informed that data collected in the 
study would be used solely for the purpose for which consent 
was obtained.6
Compensation for research participation
Study findings indicated that the issue of compensation was not 
discussed with patients most of the time. It therefore appears 
that participants were not influenced by financial inducements. 
However, it should be noted that patients may participate in re-
search even though they are not paid, since to them participa-
tion would mean securing free health care.11 Participation could 
also be due to fear of the consequences of refusal because of 
the paternalistic clinician-patient relationship.10 Given that KNH 
is a national public referral hospital, participation as a means to 
achieving cheap treatment and avoiding the long queue could 
not be ruled out.
Offering answers to questions
The researcher observed that the PGSs recruited patients dur-
ing the busy clinical schedules of attending to allocated patients. 
This could explain the below-average (46.25%) performance on 
this element. It was also observed that patients asked few ques-
tions, probably implying that they understood all the information 
presented. It could also be argued that the paternalistic nature of 
the clinician-patient relationship intimidated patients, and that the 
rapid delivery of information of 9 - 11 minutes left patients with very 
little time to ask questions.
Description of benefits
Performance on explaining direct benefits had a very good score 
of 77.5% compared with that on making participants aware of no 
clinical benefits (5%). This performance is consistent with findings 
by other researchers that 53.7% of participants recalled being 
given information on benefits only, compared with 5.2% who re-
called information on risks.6 Although some research findings indi-
cate that researchers usually emphasise benefits to limit refusal by 
prospective participants, misconceptions among participants who 
expect more medical or therapeutic benefits than explained by the 
researcher have also been reported.16,17
Option to withdraw
Although participants were told that participation was voluntary, 
they were neither told the consequences of non-participation nor 
given the option to withdraw. These omissions, in addition to em-
phasis on direct benefits, might have positively influenced par-
ticipation in the research. These findings are similar to those of 
a study in which only 21% of participants remembered being told 
that they could withdraw their consent for a study at any time with-
out giving reasons.6
Conclusion
Responsible conduct of research is critical in protecting the 
rights of Kenya’s vulnerable population. The University of Nairobi 
recognised this fact and introduced research methodology as a 
common course for all PGSs of the CHS. Moreover, all protocols 
are approved by the KNH/UoN ERC to ensure protection of par-
ticipants. A consent form containing all elements is one of the 
criteria set for approval of protocols. It is expected that all the 
PGSs who participated in the study would have had their consent 
forms approved.
However, the PGSs did not ensure that some of the basic el-
ements of informed consent were satisfactorily completed, and 
they performed better on the items that had a positive influence 
on subjects’ participation than on those that would negatively 
influence participation. The researcher noted that some PGSs 
might have failed to elicit some of the items in the elements for 
informed consent because of the nature of research that did not 
require them to elicit such items, as mentioned in the discussion. 
It seemed that the consent form was mainly used to satisfy a 
college requirement and as a legal protection tool by the PGSs, 
rather than for the purpose of obtaining informed consent in the 
true sense of the term.
Recommendations and implications for research 
ethics
A large-scale study is needed, with the sample drawn from all the 
schools of the college to confirm the practice and compare perfor-
mance in all the schools.
There is a need for additional educational programmes on bio-
ethics for postgraduate students to create greater awareness of 
the informed consent process and all its elements.
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